Novamind Inc.

Novamind Inc.

Private Company
Public Company
Subsidiary of
Clinical Immersions
Clinical Trials, R&D


Novamind ($NM | $NVMDF | $HN2) is a leading mental health company enabling safe access to psychedelic medicine through a network of clinics, retreats, and clinical research sites. Novamind provides ketamine-assisted psychotherapy and other novel treatments through its network of Cedar Psychiatry clinics and operates Cedar Clinical Research, a contract research organization specialized in clinical trials and evidence-based research for psychedelic medicine. Both Cedar Psychiatry and Cedar Clinical Research are wholly-owned subsidiaries of Novamind. For more information on how Novamind is enhancing mental wellness and guiding people through their entire healing journey, visit

Novamind is focused on three pillars: Clinical care, clinical research and a retreat network

i. Cedar Psychiatry

One of America’s leading providers of psychedelic medicine

  • Providing access to innovative, evidence based mental healthcare since 2016
  • Facilitated over 20,000 client visits in 2020, an increase of over 100% compared to the same period in 2019
  • $1.3M in fiscal Q2 revenue from four mental health clinics
  • Forecasted to increase patient volume from 20,000 client visits recorded in 2020 to approximately 65,000 client visits in 2021, +225% YoY

Treatment Options Include:

  • Ketamine-assisted therapy, the “first legal psychedelicover 7,000 treatments administered
  • SpravatoTM, an FDA-approved nasal spray version of ketamine for treatment-resistant depression and major depressive disorder with suicidal ideation or behaviour, over 2,800 treatments administered
  • Transcranial Magnetic Stimulation therapy, a non-invasive FDA-approved treatment that uses magnetic fields to stimulate areas of the brain affiliated with depression
  • Cognitive Behavioural Therapy
  • Medication management
  • Diagnostic evaluations

Clinic Locations (Utah, USA)

  • 4 clinics in operation: Springville, Orem, Draper and Layton
  • 4 clinics coming soon: Murray, Draper, Salt Lake City, Park City (July-Sept. 2021)
  • Developing a national clinic network to administer psychedelic medicine in anticipation of the FDA approval of MDMA & psilocybin in 2023 and 2025 respectively
  • Aggressively expanding via organic growth and M&A

ii. Cedar Clinical Research

An experienced host of phase I to IV clinical trials and a recognized leader in clinical research focused on psychedelics and mental health

  • Functions as a contract research organization (CRO), facilitates clinical trials on behalf of pharmaceutical companies in addition to leading internal research studies
  • Novamind’s Chief Medical Officer, Dr. Reid Robinson is a coordinating investigator of MAPS’ clinical trial examining MDMA-assisted psychotherapy as a treatment for eating disorders
  • Dr. Robison has hosted over 200 Phase I-IV clinical trials for leading pharma clients (including Johnson and Johnson)
  • Developing innovative psychedelic therapy protocols targeting difficult-to-treat mental health conditions. Protocols in development include;
  • Emotion-Focused Ketamine-Assisted Psychotherapy (EF-KAP)
  • Group Ketamine-Assisted Psychotherapy (G-KAP)
  • Hosted a pivotal ketamine study that led to the FDA-approval of SpravatoTM (the first, fast-acting drug for depression) by Janssen Pharmaceuticals
  • Currently contracted for 8 clinical trials
  • Key research site for Merck & Co.’s phase II clinical trial of MK-1942 for treatment-resistant depression 
  • Will be evaluated as a research site for Bionomics’ phase II clinical trial of BNC210 for PTSD
  • Novamind is a strategic investor in Bionomics 
  • Co-investors include: Apeiron, Biotech Value Fund, Merck, Mike Novogratz, and Peter Thiel
  • Research partners include:


iii. Retreat network

Novamind is building a network of psychedelic retreats in jurisdictions with established regulations for the use of psychedelics. It has strategic investments in the Netherlands-based Synthesis Institute and the Costa Rica-based Circadia Center

  • Synthesis was founded in 2018 and has hosted medically supervised psilocybin retreats for more than 600 participants
  • Circadia expects to host its first psychedelic retreat post COVID-19